TNNT2 and type 2 diabetes mellitus: A secondary analysis of the ADVANCE trial showed that NT-proBNP and hs-cTnT were strongly associated with an increased risk of MACE and death over a 5 year follow-up period, even after extensive adjustment for established and emerging clinical predictors of outcome in T2DM [45].